Hematologic Oncology

The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.

Carlos R. Bachier, MD, director, blood and marrow transplant research, Sarah Cannon Research Institute, discusses toxicities associated with stem cell transplant.

Alan Skarbnik, MD, staff physician, Department of Bone Marrow Transplantation and Department of Lymphoma, John Theurer Cancer Center, discusses the use of chemotherapy in patients with chronic lymphocytic leukemia (CLL).

Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).

The FDA has approved blinatumomab for the treatment of patients with minimal residual disease–positive B-cell precursor acute lymphoblastic leukemia.

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses ongoing trials in hematologic malignancies.

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial (NCT03391466) in diffuse large B-cell lymphoma (DLBCL).

Ponatinib maintained deep, durable responses in heavily pretreated patients with chronic-phase chronic myeloid leukemia (CP-CML).

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations under investigation in acute leukemia.

Neil E. Kay, MD, discusses the available options and sequencing challenges for patients with relapsed/refractory chronic lymphocytic leukemia, as well as next steps for advancing outcomes for this patient population.

The FDA has approved brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma.

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of brentuximab vedotin (Adcetris) combined with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for patients with advanced classical Hodgkin lymphoma.

Breakthrough gene therapy for B-cell lymphoma now available at Hackensack University Medical Center.

Fostamatinib resulted in clinically meaningful, ongoing platelet responses and a low rate of bleeding events in 43% of patients with chronic immune thrombocytopenic purpura with long-disease duration.

Andrew Laramore, MD, Anatomic and Clinical Pathology, Diagnostic Pathology Services, discusses some of the known genes that are tested for in hematologic malignancies.

Nichon L. Grupka, MD, discusses advances in hematopathology, specifically mutations as prognostic indicators, disease-associated versus disease-causing mutations, and advice for physicians who are working to navigate the field.

IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion (IKZF1plus) were associated with a dramatically reduced prognosis in pediatric patients with B-cell precursor ALL.

Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the role of combinations in the treatment of patients with chronic lymphocytic leukemia (CLL).

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the current landscape of myelodysplastic syndromes (MDS).